Novartis's Cosentyx Climbs Despite Competitors And COVID-19
First Billion Dollar Quarter For Anti-IL-17 Blockbuster
CEO Vas Narasimhan told Scrip how impressed he was by the resilience of the brand and while Cosentyx is holding its market share in dermatology, its rheumatology sales are continuing to fly high.
You may also be interested in...
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
As well as highlighting Novartis's burgeoning pipeline, the Swiss major's CEO is confident that its biggest earners will continue to growth for the next five years at least.